Amedisys (AMED) PT Raised to $133 at RBC Capital
RBC Capital analyst Frank Morgan raised the price target on Amedisys (NASDAQ: AMED) to $133.00 (from $126.00) while maintaining a Outperform rating following solid Q4.
RBC Capital analyst Frank Morgan raised the price target on Amedisys (NASDAQ: AMED) to $133.00 (from $126.00) while maintaining a Outperform rating following solid Q4.